Personalized dose selection for the first Waldenstrom macroglobulinemia patient on the PRECISE CURATE.AI trial.

ABSTRACT: The digital revolution in healthcare, amplified by the COVID-19 pandemic and artificial intelligence (AI) advances, has led to a surge in the development of digital technologies. However, integrating digital health solutions, especially AI-based ones, in rare diseases like Waldenström macroglobulinemia (WM) remains challenging due to limited data, among other factors. CURATE.AI, a clinical decision support system, offers an alternative to big data approaches by calibrating individual treatment profiles based on that individual's data alone. We present a case study from the PRECISE CURATE.AI trial with a WM patient, where, over two years, CURATE.AI provided dynamic Ibrutinib dose recommendations to clinicians (users) aimed at achieving optimal IgM levels. An 80-year-old male with newly diag

SUBMITTER: Blasiak A 

PROVIDER: S-EPMC11350179 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature